Wednesday, April 2, 2025 4/2/2025

Vanderbilt HIV Clinical Trials Unit (CTU)

Award Number: UM1AI069439
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Vanderbilt HIV Clinical Trials Unit (CTU) - PROJECT SUMMARY/ABSTRACT The HIV pandemic is one of the greatest ongoing threats to health and development, over 35 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field, which will contribute to ultimately ending the HIV epidemic. The Vanderbilt HIV Clinical Trials Unit (CTU) will continue the established partnership between Vanderbilt University Medical Center in Nashville, Tennessee, and Washington University in St. Louis, Missouri, which are located in a region of the United States with high incidence and prevalence of HIV. This CTU comprises three highly productive Clinical Research Sites (CRSs) that contribute to three Networks - the therapeutics mission of the AIDS Clinical Trials Group (ACTG), the vaccine mission of the HIV Vaccine Trials Network (HVTN), and the non- vaccine prevention mission of the HIV Prevention Trials Network (HPTN). The Vanderbilt Vaccine CRS and Washington University Therapeutics CRS have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The Vanderbilt Therapeutics CRS joined the ACTG in 2000. To contribute more broadly to the Networks, Washington University has provided protocol-specific enrollment to the HPTN since 2016, and proposes to become a full member site of the HPTN, as the Washington University Prevention & Therapeutics CRS. Leaders of this CTU have made high-impact scientific and programmatic contributions to the Networks in areas that include human genomics, contemporary HIV-associated comorbidities, neurological aspects of HIV disease, immunology of vaccine response, and beyond. During the proposed funding period, the Vanderbilt CTU will continue to make substantial contributions to the ACTG, HVTN and HPTN's scientific priorities. ACTG sites at both Vanderbilt and Washington University will focus on strategies to improve the health of people living with HIV/AIDS, tuberculosis, and viral hepatitis. The Vanderbilt HVTN site will contribute both study participants and cutting-edge immunologic technologies to further the major scientific priority of developing and testing a safe and effective vaccine for HIV. The Washington University site will additionally contribute to HPTN's emphasis on long-acting agents for pre-exposure prophylaxis, developing multipurpose technologies such as combining HIV prevention with contraception, and strategies integrating biomedical, behavioral and structural interventions for prevention. All CRSs of this CTU have an established record of success in enrolling participants to clinical trials and conducting studies with utmost fidelity to ensure participant safety and quality data advancing the science of HIV treatment and prevention.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,360,105 )
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	20	11/26/2024	NON-COMPETING CONTINUATION	$1,360,105
														Subtotal = $1,360,105

Issue Date FY: 2024 ( Subtotal = $2,649,501 )
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	19	6/12/2024	NON-COMPETING CONTINUATION	$1,324,750
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	19	11/8/2023	NON-COMPETING CONTINUATION	$1,324,751
														Subtotal = $2,649,501

Issue Date FY: 2023 ( Subtotal = $2,106,727 )
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	18	6/9/2023	NON-COMPETING CONTINUATION	$1,269,849
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	18	11/21/2022	NON-COMPETING CONTINUATION	$836,878
														Subtotal = $2,106,727

Issue Date FY: 2022 ( Subtotal = $2,679,601 )
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	17	6/3/2022	NON-COMPETING CONTINUATION	$1,045,044
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	17	11/24/2021	NON-COMPETING CONTINUATION	$1,634,557
														Subtotal = $2,679,601

Issue Date FY: 2021 ( Subtotal = $2,272,138 )
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	003	16	7/22/2021	COMPETING CONTINUATION	$205,539
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	16	3/17/2021	COMPETING CONTINUATION	$1,324,521
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	16	11/16/2020	COMPETING CONTINUATION	$1,253,091
2021	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	004	15	7/22/2021	SUPPLEMENT FOR EXPANSION	-$305,474
2021	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	002	15	7/22/2021	NON-COMPETING CONTINUATION	-$205,539
														Subtotal = $2,272,138

Issue Date FY: 2020 ( Subtotal = $3,045,839 )
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	15	11/19/2019	NON-COMPETING CONTINUATION	$1,453,087
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	002	15	6/4/2020	NON-COMPETING CONTINUATION	$1,034,346
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	15	6/2/2020	SUPPLEMENT FOR EXPANSION	$558,406
														Subtotal = $3,045,839

Issue Date FY: 2019 ( Subtotal = $2,941,559 )
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	14	5/23/2019	NON-COMPETING CONTINUATION	$1,470,779
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	14	11/20/2018	NON-COMPETING CONTINUATION	$1,470,780
														Subtotal = $2,941,559

Issue Date FY: 2018 ( Subtotal = $1,615,311 )
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	002	13	5/14/2018	NON-COMPETING CONTINUATION	$807,655
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	13	11/20/2017	NON-COMPETING CONTINUATION	$538,437
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	13	2/19/2018	NON-COMPETING CONTINUATION	$269,219
														Subtotal = $1,615,311

Issue Date FY: 2017 ( Subtotal = $1,003,759 )
2017	2017	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	12	11/17/2016	NON-COMPETING CONTINUATION	$1,003,759
														Subtotal = $1,003,759

Issue Date FY: 2016 ( Subtotal = $1,620,286 )
2016	2016	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	002	11	5/9/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,224,853
2016	2016	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	10	5/9/2016	NON-COMPETING CONTINUATION	-$1,219,877
2016	2016	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	10	11/12/2015	NON-COMPETING CONTINUATION	$1,615,310
														Subtotal = $1,620,286

Issue Date FY: 2015 ( Subtotal = $1,603,813 )
2015	2015	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	9	11/12/2014	NON-COMPETING CONTINUATION	$1,578,046
2015	2015	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	9	6/25/2015	NON-COMPETING CONTINUATION	$25,767
														Subtotal = $1,603,813

Issue Date FY: 2014 ( Subtotal = $2,716,438 )
2014	2014	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	002	8	2/21/2014	COMPETING CONTINUATION	$270,235
2014	2014	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	8	12/10/2013	COMPETING CONTINUATION	$1,415,498
2014	2014	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	8	12/26/2013	COMPETING CONTINUATION	$1,030,705
														Subtotal = $2,716,438

Issue Date FY: 2013 ( Subtotal = $1,209,774 )
2013	2013	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	7	6/12/2013	NON-COMPETING CONTINUATION	$180,976
2013	2013	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	7	12/1/2012	NON-COMPETING CONTINUATION	$1,028,798
														Subtotal = $1,209,774

Issue Date FY: 2012 ( Subtotal = $1,917,163 )
2012	2012	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	6	12/22/2011	NON-COMPETING CONTINUATION	$1,725,447
2012	2012	VANDERBILT UNIVERSITY HOSPITAL, CHILDREN'S REHAB UNIT	1161 21ST AVENUE SOUTH	NASHVILLE	TN	37232	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	6	3/5/2012	NON-COMPETING CONTINUATION	$191,716
														Subtotal = $1,917,163

Grand Total All Awards = $28,742,014

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Vanderbilt HIV Clinical Trials Unit (CTU)

Award Number: UM1AI069439

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer